1. Главная
  2. Ресурсы
  3. Библиотечный поиск
Genetic Heterogeneityin Therapy-NaïveSynchronous PrimaryBreast Cancers andTheir Metastases Charlotte K.Y. NgFrançois‐Clément BidardSalvatore Piscuoglio2017 год

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: Purpose: Paired primary breast cancers and metachronous metastases after adjuvant treatment are reported to differ in their clonal composition and genetic alterations, but it is unclear whether these differences stem from the selective pressures of the metastatic process, the systemic therapies, or both. We sought to define the repertoire of genetic alterations in breast cancer patients with de novo metastatic disease who had not received local or systemic therapy.Experimental Design: Up to two anatomically distinct core biopsies of primary breast cancers and synchronous distant metastases from nine patients who presented with metastatic disease were subjected to high-depth whole-exome sequencing. Mutations, copy number alterations and their cancer cell fractions, and mutation signatures were defined using state-of-the-art bioinformatics methods. All mutations identified were validated with orthogonal methods.Results: Genomic differences were observed between primary and metastatic deposits, with a median of 60% (range 6%-95%) of shared somatic mutations. Although mutations in known driver genes including TP53, PIK3CA, and GATA3 were preferentially clonal in both sites, primary breast cancers and their synchronous metastases displayed spatial intratumor heterogeneity. Likely pathogenic mutations affecting epithelial-to-mesenchymal transition-related genes, including SMAD4, TCF7L2, and TCF4 (ITF2), were found to be restricted to or enriched in the metastatic lesions. Mutational signatures of trunk mutations differed from those of mutations enriched in the primary tumor or the metastasis in six cases.Conclusions: Synchronous primary breast cancers and metastases differ in their repertoire of somatic genetic alterations even in the absence of systemic therapy. Mutational signature shifts might contribute to spatial intratumor genetic heterogeneity. Clin Cancer Res; 23(15); 4402-15. ©2017 AACR.
Год издания: 2017
Авторы: Charlotte K.Y. Ng, François‐Clément Bidard, Salvatore Piscuoglio, Felipe C. Geyer, Raymond S. Lim, Ino de Bruijn, Ronglai Shen, Fresia Pareja, Samuel H. Berman, Lu Wang, Jean‐Yves Pierga, Anne Vincent‐Salomon, Agnès Viale, Larry Norton, Brigitte Sigal, Britta Weigelt, Paul Cottu, Jorge S. Reis‐Filho
Издательство: American Association for Cancer Research
Источник: Clinical Cancer Research
Ключевые слова: Cancer Genomics and Diagnostics, Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies
Другие ссылки: Clinical Cancer Research (PDF)
Clinical Cancer Research (HTML)
edoc (University of Basel) (HTML)
Europe PMC (PubMed Central) (PDF)
Europe PMC (PubMed Central) (HTML)
PubMed Central (HTML)
aacr.figshare.com (PDF)
doi.org (HTML)
aacr.figshare.com (PDF)
doi.org (HTML)
aacr.figshare.com (PDF)
doi.org (HTML)
aacr.figshare.com (PDF)
doi.org (HTML)
aacr.figshare.com (PDF)
doi.org (HTML)
aacr.figshare.com (PDF)
doi.org (HTML)
aacr.figshare.com (PDF)
doi.org (HTML)
aacr.figshare.com (PDF)
doi.org (HTML)
PubMed (HTML)